JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

New USP Chapters <72> and <86> for Testing Pharmaceuticals for Sterility and Endotoxins

  • 0Independent Consultant, Copell, Texas. RLisaDAshworth@gmail.com.
International Journal of Pharmaceutical Compounding +

|

March 31, 2025

|

March 31, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

The pharmaceutical industry is shifting away from animal-derived substances for medications and tests due to various concerns. Developing synthetic alternatives can be a complex process, varying in speed based on the specific substance and public health demands.

Area Of Science

  • Pharmaceutical Science
  • Biotechnology
  • Drug Development

Background

  • The pharmaceutical sector has a long-standing trend towards reducing reliance on animal-derived materials.
  • Key drivers include concerns over animal diseases, supply shortages of animal-sourced components, and ethical considerations.

Purpose Of The Study

  • To explore the pharmaceutical industry's transition from animal-derived to synthetic substances.
  • To examine the factors influencing the development and adoption of non-animal-derived alternatives.

Main Methods

  • Review of industry trends and historical data on pharmaceutical development.
  • Analysis of case studies on the transition from animal-derived to synthetic components.
  • Evaluation of factors affecting the speed of synthetic alternative development.

Main Results

  • The shift towards non-animal-derived substances is a multi-faceted and ongoing process.
  • The timeline for developing synthetic replacements is highly variable, influenced by scientific complexity and urgency.
  • Public health needs significantly impact the pace of this transition.

Conclusions

  • The pharmaceutical industry's move to synthetic alternatives is driven by practical and safety considerations.
  • Successful development and implementation of synthetic substances require a balance between scientific feasibility and public health imperatives.
  • Continued innovation is crucial for accelerating the adoption of non-animal-derived pharmaceuticals.